Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in acute myocardial infarction
NCT05284747Phase 4Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2022
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of evolocumab in myocardial infarction (MI), sponsored by Amgen. Started Oct 2022; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05284747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284747.